Stereotactic body radiotherapy appeared safe and effective for men with high-risk prostate cancer, according to an analysis of data from a consortium of seven institutional phase 2 studies and registries.
The analysis, published in International Journal of Radiation Oncology, Biology, Physics, showed that the 5-day regimen of higher-dose radiotherapy had a 4-year cure rate of 82%.